Abstract
A growing body of evidence suggests that omega (ω)-3 polyunsaturated fatty acids (PUFAs) are clinically useful in patients with psychiatric disorders. In the present review, we summarize the findings of randomized, placebocontrolled clinical trials that have focused on the potential therapeutic utility of ω-3 PUFAs in patients with mental illnesses. We searched the PubMed database for placebo-controlled clinical trials using the keywords “PUFAs”, “omega-3”, “eicosapentaenoic acid”, and “docosahexaenoic acid” in combination with the following terms: “anxiety disorders”, “mood disorders”, “autism”, “attention-deficit hyperactivity disorder” (ADHD), “personality disorders”, and “schizophrenia”. The literature review indicated that personality disorders, autism, and anxiety disorders have been investigated less frequently than mood disorders, schizophrenia, and ADHD. Although no definite conclusions can be drawn on the therapeutic efficacy of ω-3 PUFAs in the majority of the psychiatric illnesses examined here, the evidence suggests that these molecules have a potential preventive role in people at extremely high risk for developing psychosis. Future studies in the field should examine ω-PUFAs turnover in neural membranes. Moreover, special attention should be paid to potential confounds, such as smoking and dietary habits.
Keywords: Docosahexaenoic acid, eicosapentaenoic acid, omega-3, psychiatric disorders, trials.
Current Drug Discovery Technologies
Title:Randomized Placebo-Controlled Trials of Omega-3 Polyunsaturated Fatty Acids in Psychiatric Disorders: A Review of the Current Literature
Volume: 10 Issue: 3
Author(s): Pierluigi Politi, Matteo Rocchetti, Enzo Emanuele, Mariangela Rondanelli and Francesco Barale
Affiliation:
Keywords: Docosahexaenoic acid, eicosapentaenoic acid, omega-3, psychiatric disorders, trials.
Abstract: A growing body of evidence suggests that omega (ω)-3 polyunsaturated fatty acids (PUFAs) are clinically useful in patients with psychiatric disorders. In the present review, we summarize the findings of randomized, placebocontrolled clinical trials that have focused on the potential therapeutic utility of ω-3 PUFAs in patients with mental illnesses. We searched the PubMed database for placebo-controlled clinical trials using the keywords “PUFAs”, “omega-3”, “eicosapentaenoic acid”, and “docosahexaenoic acid” in combination with the following terms: “anxiety disorders”, “mood disorders”, “autism”, “attention-deficit hyperactivity disorder” (ADHD), “personality disorders”, and “schizophrenia”. The literature review indicated that personality disorders, autism, and anxiety disorders have been investigated less frequently than mood disorders, schizophrenia, and ADHD. Although no definite conclusions can be drawn on the therapeutic efficacy of ω-3 PUFAs in the majority of the psychiatric illnesses examined here, the evidence suggests that these molecules have a potential preventive role in people at extremely high risk for developing psychosis. Future studies in the field should examine ω-PUFAs turnover in neural membranes. Moreover, special attention should be paid to potential confounds, such as smoking and dietary habits.
Export Options
About this article
Cite this article as:
Politi Pierluigi, Rocchetti Matteo, Emanuele Enzo, Rondanelli Mariangela and Barale Francesco, Randomized Placebo-Controlled Trials of Omega-3 Polyunsaturated Fatty Acids in Psychiatric Disorders: A Review of the Current Literature, Current Drug Discovery Technologies 2013; 10 (3) . https://dx.doi.org/10.2174/1570163811310030007
DOI https://dx.doi.org/10.2174/1570163811310030007 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Endocannabinoid System in Neurological Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Nanotechnology Driven Approaches for the Management of Parkinson’s Disease: Current Status and Future Perspectives
Current Drug Metabolism Applications of Nanotechnology in Diagnostics and Therapeutics of Alzheimer’s and Parkinson’s Disease
Current Drug Metabolism Aripiprazole in Children and Adolescents with Schizophrenia
Current Psychopharmacology Advances in the Treatment of Neurodegenerative Disorders Employing Nanoparticles
Recent Patents on Drug Delivery & Formulation New Trends in the Treatment of Schizophrenia
CNS & Neurological Disorders - Drug Targets Association of Posture Instability with Dopamine Drop of Nigrostriatal System and Hypometabolism of Cerebral Cortex in Parkinson’s Disease
Current Neurovascular Research Hyperhomocysteinemia in Movement Disorders: Current Evidence and Hypotheses
Current Vascular Pharmacology Ginkgo biloba Extract 761: A Review of Basic Studies and Potential Clinical Use in Psychiatric Disorders
CNS & Neurological Disorders - Drug Targets A Case of Akathisia induced by Escitalopram: Case Report & Review of Literature
Current Drug Safety Mitochondrial Toxins in Basal Ganglia Disorders: From Animal Models to Therapeutic Strategies
Current Neuropharmacology Receptor-Binding and Pharmacokinetic Properties of Dopaminergic Agonists
Current Topics in Medicinal Chemistry NOS: Molecular Mechanisms, Clinical Aspects, Therapeutic and Monitoring Approaches
Current Drug Targets - Inflammation & Allergy Dietary Phytoestrogens: Neuroprotective Role in Parkinson’s Disease
Current Neurovascular Research Patterns of Self-Medication with Medicinal Plants and Related Adverse Events - A South American Survey
Current Drug Safety Do mtDNA Mutations Participate in the Pathogenesis of Sporadic Parkinsons Disease?
Current Genomics Pharmacokinetics, Disposition, and Metabolism of [14C]-Nebicapone in Humans
Drug Metabolism Letters Does Phosphodiesterase 11A (PDE11A) Hold Promise as a Future Therapeutic Target?
Current Pharmaceutical Design Adult Neurogenesis and Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Current Trends on Antipsychotics: Focus on Asenapine
Current Medicinal Chemistry